ClinicalTrials.gg
CompletedNCT06521931Updated Mar 2, 2026

A Study of PN20 for the Prevention of Chemotherapy-induced Thrombocytopenia in Lymphoma or Solid Tumor Patients

A Phase 1 interventional study of PN20 in Thrombocytopenia, sponsored by Chongqing Peg-Bio Biopharm Co., Ltd.. Completed at 6 sites in China. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-03-02.

Sponsored by Chongqing Peg-Bio Biopharm Co., Ltd. · Phase 1, Interventional, and Prevention

From the registry’s dates

  • Registered 7 months after the study started (first participant enrolled Dec 2023, registered Jul 2024).

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
24
Allocation
Not applicable
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 108 studies in Thrombocytopenia with a site in China — 42 open to participants now, 45 under way, 10 of them phase 3. Thrombocytopenia · China.

Enrollment
84th of 96
24 · median 82
Started
2023
with 9 others
Phase 1
8 of 108
3 open now
Registered
77th of 108
by date

Among the 108 studies in Thrombocytopenia with a site in China, this one is the 84th largest by enrollment of the 96 interventional ones that give a count, is one of 10 that started in 2023, is one of 8 in phase 1, and was the 77th registered.

Thrombocytopenia

484 studies on the registry are indexed under Thrombocytopenia; 102 are open to participants now.

Browse Thrombocytopenia studies →

Open to participants now

42 of the 108 studies in Thrombocytopenia with a site in China are open now. Recruiting first, the newest first:

37 more — sign in →

All 42 open studies →

A study can be open while its sites in China have not opened yet or have stopped. Only those recruiting at a site in China →

Who these studies take

Of the 66 Thrombocytopenia studies recruiting now, 44 (67%) set no upper age limit and 18 (27%) stop at 75 or younger; 10 take children under 18; 3 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 108 studies in Thrombocytopenia with a site in China, or all of them as a file.
02

Study summary

The main aim of this clinical trial is to assess the safety and tolerability of PN20 in adult patients with chemotherapy-induced thrombocytopenia (CID). The main questions it aims to answer are:

  • Is PN20 safe in these patients?
  • Could these patients potentially benefit from PN20 prevention? Participants will
  • Receive subcutaneous injections of PN20 according to weight on the first day of chemotherapy cycle, within 1 hour before the administration of chemotherapy drugs,
  • Visit the clinic on Day 1 (D1), D2, D3, D4, D5, D8, D11, D13, D15 and D21 for assessment.
Read the detailed description

This is a multicenter, single-arm, open-label, dose escalation study to evaluate the safety, tolerability, pharmacokinetic, pharmacodynamics and immunogenicity of PN20 for the Prevention of Chemotherapy-induced Thrombocytopenia in Adult Patients With Lymphoma or Solid Tumor.

This study was divided into two phase, single-dose and multiple-dose. After single-dose period (21 days), if the subject meets the multiple-dose criteria, he or she can enter the multiple-dose phase for the second cycle of PN20 prevention. Subjects could receive a maximum of two cycles of PN20 prevention.

03

Conditions studied

  • Thrombocytopenia

Browse trials for

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Aged ≥ 18 years, regardless of gender;
  2. Diagnosed with lymphoma or solid tumor by pathological histology or cytology examination;
  3. Currently receiving a 21-day chemotherapy regimen, using one or more of the following or similar drugs: gemcitabine; platinums, including carboplatin, nedaplatin, cisplatin, lobaplatin, etc.; anthracyclines, including doxorubicin, daunorubicin, epirubicin, etc.; taxanes, including paclitaxel, docetaxel, etc.; alkylating agents, including cyclophosphamide, ifosfamide, etc.;
  4. The current chemotherapy regimen should be consistent with that of the previous chemotherapy cycle before enrollment, including the type and dosage of the drugs, and no medication or dosage adjustments are allowed;
  5. count (PLT) was between 75 and 150×10\^9/L (including the critical value) one day before the start of chemotherapy in the first treatment cycle or before enrollment;
  6. There was a decrease in PLT to 25×10\^9/L≤ PLT \<75×10\^9/L during the previous chemotherapy cycle before enrollment;
  7. Expected survival ≥ 12 weeks;
  8. (ECOG) Physical Score is ≤ 2;
  9. No fertility plan during the trial and within 6 months after the end of the follow-up, and agree to take medically recognized measures (such as complete abstinence, condoms, contraceptive rings, ligation, drug contraception, etc.) to avoid pregnancy for themselves or their partners;
  10. Be able to understand the requirements and procedures of the protocol, voluntarily participate and sign the form.

Exclusion criteria

Exclusion Criteria:

  1. With thrombocytopenia caused by non-chemotherapy within 6 months before screening, including but not limited to ethylenediaminetetraacetic acid (EDTA)-dependent pseudothrombocytopenia, hypersplenism, infection and bleeding;
  2. With other hematopoietic diseases other than lymphoma and chemotherapy induced thrombocytopenia, including leukemia, primary immune thrombocytopenia, myeloproliferative diseases, multiple myeloma and myelodysplastic syndrome;
  3. The tumor has already undergone bone marrow invasion or ;
  4. With active central nervous system metastasis (such as clinical symptoms, cerebral edema, requiring hormone intervention (excluding maintenance of low-dose hormones)), progression of , and carcinomatous meningitis. Subjects with previously treated brain metastases who meet the following conditions may participate in the study: clinical stability has been maintained for ≥ 2 months, and systemic hormone therapy (prednisone or other equivalent doses of hormones at a dose of >10 mg/day) has been discontinued for >4 weeks;
  5. Acute or active bleeding of clinical significance (such as gastrointestinal or central nervous system) within 7 days before screening;
  6. Have a history of any arteriovenous thrombosis within 6 months before screening;
  7. Have a history of major cardiovascular disease within 6 months before screening (such as congestive heart failure ( (NYHA) heart function score III-IV), arrhythmias known to increase the risk of thromboembolic events (atrial fibrillation, etc.), coronary stent implantation, angioplasty or coronary artery bypass grafting);
  8. Accompanying diseases that the investigator believes the drug may cause unnecessary risks of, such as: severe cardiovascular and cerebrovascular diseases, digestive system diseases, liver and kidney dysfunction diseases, or a family history of mental illness;
  9. Laboratory examination abnormalities during the screening period (baseline), such as:

    1. Blood biochemistry: (ALT), aspartate aminotransferase (AST), total ≥ 3 times the (ULN) (if liver metastasis exists, ALT, AST, total bilirubin can be ≥ 5 × ULN); serum creatinine ≥ 1.5 × ULN;
    2. Blood routine: absolute neutrophil value \<1.5×10\^9/L; \< 80 g/L;
  10. Abnormal of clinical significance during screening or prolonged /QTc interval, such as QTcF ≥ 450ms (male) or 470ms (female); family history of QT prolongation;
  11. Active (hepatitis B virus titer > 1,000 copies/ml or 200IU/ml); virus infection (HCV-RNA Above the detection limit); preventive antiviral treatment other than interferon is allowed. For patients with hepatocellular carcinoma (HCC), hepatitis B virus titer> 10,000 copies/ml or 2000IU/ml; antibody (HIV), syphilis positive;
  12. Received transfusion within 5 days before the first dose;
  13. Anticoagulants (heparin, warfarin, apixaban, bivalirudin, etc.), antiplatelet drugs (clopidogrel, aspirin, etc.), fibrinolytic drugs (urokinase, etc.) were used for prevention or treatment within 1 week before the first dose;
  14. Received other drugs with platelet-raising effects (e.g., caffeic acid tablets, leucogen tablets, aminopeptide tablets, or platelet-raising capsules, etc.) within 1 week before the first dose; received recombinant human thrombopoietin (rh-TPO) or used recombinant human interleukin-11 (rhIL-11), thrombopoietin receptor agonist (TPO-RA) within 10 days before the first dose or 5 half-lives of the drug (whichever is longer);
  15. Currently receiving or received radiotherapy within 3 months before screening;
  16. Received bone marrow transplantation or stem cell infusion within 1 year before screening;
  17. Allergic to the investigational drug or (such as histidine, glycine, mannitol, sucrose) or previously experienced life-threatening systemic allergic reaction;
  18. Used other clinical trial drugs or devices within 4 weeks before the first dose;
  19. Other conditions the investigator believes would be unsuitable for participation in this clinical study.
Terms in these criteria, in plain language(18)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

Brain metastases

Cancer deposits in the brain from a cancer that started elsewhere in the body (CNS metastases include the spinal cord).

Studies differ: some leave out any brain metastases, some accept ones treated and stable for some weeks. Check what this study allows.

NYHA class (heart failure)

The New York Heart Association’s four classes of how much heart failure limits physical activity.

I
No limits: ordinary activity causes no undue tiredness or breathlessness.
II
Slight limits: comfortable at rest, ordinary activity causes symptoms.
III
Marked limits: comfortable at rest, less than ordinary activity causes symptoms.
IV
Symptoms even at rest; any activity makes them worse.

Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

QT and QTc

On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.

The study may name a correction formula and a limit in milliseconds, often around 450–480.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Excipients

The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.

05

Study design

Phase
Phase 1
Primary purpose
Prevention
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
24 participants (actual)

Study arms

  • Experimental
    PN20 group

    thrombopoietin receptor agonist

    Drug: PN20

Interventions

  • DrugPN20

    Three dose cohorts: 0.2, 0.5 and 0.75 mg/kg, subcutaneous injections, on Day 1 of chemotherapy cycle before the administration of chemotherapy drugs

06

What researchers measure

Primary outcomes

  1. AE in single-dose phase

    The incidence of adverse events related to PN20 within 21 days after a single dose

    Time frame: Day 1-21 of Cycle 1 (each cycle is 21 days)

  2. The proportion of patients with PLT ≥ 100×10^9/L in multiple-dose phase

    The proportion of subjects whose platelet count (PLT) reached ≥ 100 × 10\^9/L at the end of the second chemotherapy cycle.

    Time frame: Day 21 of Cycle 2 (each cycle is 21 days)

07

Study locations

6 sites
  • Affiliated Hospital of Hebei University
    Baoding, Hebei 071000, China
  • The First Affiliated Hospital of Henan University of Science and Technology
    Luoyang, Henan 471003, China
  • Henan Cancer Hospital
    Zhengzhou, Henan 450008, China
  • Yiyang Central Hospital
    Yiyang, Hunan 413099, China
  • The Affiliated Hospital of Qingdao University
    Qingdao, Shandong 266057, China
  • Affiliated Hospital of Southwest Medical University
    Luzhou, Sichuan 646000, China
08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Dec 2023 to primary completion in Jan 2025, 13 months.

Of 18 phase 1 interventional studies under Thrombocytopenia, half reached primary completion within 15 months of starting (the median), counting those still running; a quarter within 6 and three quarters within 36. This study's 13 months is below that.

How these figures are worked out, and which studies are left out of them.

Registered
Jul 18, 2024
First posted
Jul 26, 2024
StartActual
Dec 6, 2023
Primary completionActual
Jan 13, 2025
CompletionActual
Jan 13, 2025
Last update
Mar 2, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Mar 2, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT06521931
Responsible party
Sponsor
First posted
Jul 26, 2024
Start date
Dec 6, 2023
Primary completion
Jan 13, 2025
Completion
Jan 13, 2025
Last update
Mar 2, 2026

Study contacts

Suxia Luo
principal investigator · Henan Cancer Hospital

Oversight

FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Feb 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: PN20

Start the discussion